Professor Kumlesh Dev

• Rutkowska, A. Preuss, I. Gessier, F. Sailer, A.W. Dev, K.K., EBI2 regulates intracellular signaling and migration in human astrocyte, Glia, 63, (2), 2015, p341 - 351Journal Article, 2015, DOI , URL
• O'Connell, K.E. Thakore, J. Dev, K.K., Increased interleukin 23 (IL23) levels in schizophrenia patients treated with depot antipsychotic medication, Cytokine, 73, (1), 2014, p196-198Journal Article, 2014, DOI , URL
• Muirhead, G. Dev, K.K., The expression of neuronal sorting nexin 8 (SNX8) exacerbates abnormal cholesterol levels, Journal of Molecular Neuroscience, 53, (1), 2014, p125 - 134Journal Article, 2014, DOI , URL
• O'Connell, K.E. Mok, T. Sweeney, B. Ryan, A.M. Dev, K.K., The use of cytokine signature patterns: Separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients, Autoimmunity, 47, (8), 2014, p505 - 511Journal Article, 2014, DOI , URL
• Elain, G. Jeanneau, K. Rutkowska, A. Mir, A.K. Dev, K.K., The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes, Glia, 62, (5), 2014, p725 - 735Journal Article, 2014, DOI , URL
• O'Sullivan S, Dev K.K, Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases, Neuropharmacology, 113, 2017, p597 - 607Journal Article, 2017, DOI , URL
• Dev K.K, Irving A.J, Lipid sensing G protein-coupled receptors in the CNS, Neuropharmacology, 113, 2017, p595 - 596Journal Article, 2017, DOI , URL
• O'Sullivan S.A, Velasco-Estevez M, Dev K.K, Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors, GLIA, 2017, p23148-Journal Article, 2017, DOI , URL
• Madill M, Fitzgerald D, O'Connell K.E, Dev K.K, Shen S, FitzGerald U, In vitro and ex vivo models of multiple sclerosis, Drug Discovery Today, 21, (9), 2016, p1504 - 1511Journal Article, 2016, DOI , URL
• O'Sullivan S.A, Gasparini F, Mir A.K, Dev K.K, Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes, Journal of Neuroinflammation, 13, (1), 2016, p189-Journal Article, 2016, DOI , URL , TARA - Full Text
• Rutkowska A, O'Sullivan S.A, Christen I, Zhang J, Sailer A.W, Dev K.K, The EBI2 signalling pathway plays a role in cellular crosstalk between astrocytes and macrophages, Scientific Reports, 6, 2016, p25520 -Journal Article, 2016, DOI , URL , TARA - Full Text
• O'Sullivan C, Schubart A, Mir A.K, Dev K.K, The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures, Journal of Neuroinflammation, 13, (1), 2016, p31-Journal Article, 2016, DOI , URL , TARA - Full Text
• Dev K.K, Common receptor signalling in glial & immune cells, Current Drug Targets, 17, (16), 2016, p1828-Journal Article, 2016, URL
• O'Sullivan C, Dev K.K, Galactosylsphingosine (psychosine)-induced demyelination is attenuated by sphingosine 1-phosphate signalling, Journal of Cell Science, 128, (21), 2015, p3878 - 3887Journal Article, 2015, DOI , URL , TARA - Full Text
• Rutkowska, A. and Shimshek, D.R. and Sailer, A.W. and Dev, K.K., EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes, Neuropharmacology, 133, 2018, p121-128Journal Article, 2018, DOI , URL , TARA - Full Text
• O'Sullivan, S.A. and O'Sullivan, C. and Healy, L.M. and Dev, K.K. and Sheridan, G.K., Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia, Journal of Neurochemistry, 2018Journal Article, 2018, DOI , URL , TARA - Full Text
• Rutkowska, A. and Sailer, A.W. and Dev, K.K., EBI2 receptor regulates myelin development and inhibits LPC-induced demyelination, Journal of Neuroinflammation, 14, (1), 2017, p250-Journal Article, 2017, DOI , URL , TARA - Full Text
• Misslin, C. and Velasco-Estevez, M. and Albert, M. and O†Sullivan, S.A. and Dev, K.K., Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination, PLoS ONE, 12, (11), 2017, e0187217-Journal Article, 2017, DOI , URL , TARA - Full Text
• O'Sullivan, S.A. and Dev, K.K., The chemokine fractalkine (CX3CL1) attenuates H2O2-induced demyelination in cerebellar slices, Journal of Neuroinflammation, 14, (1), 2017, p159-Journal Article, 2017, DOI , URL , TARA - Full Text
• Dutta, P. and Dargahi, L. and O'Connell, K.E. and Bolia, A. and Ozkan, B. and Sailer, A.W. and Dev, K.K., A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease, Neuroscience Letters, 673, 2018, p12-18Journal Article, 2018, DOI , URL
• Velasco-Estevez M, Mampay M, Boutin H, Chaney A, Warn P, Sharp A, Burgess E, Moeendarbary E, Dev KK, Sheridan GK., Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes., Front Aging Neurosci, 2018, p332-Journal Article, 2018, TARA - Full Text
• Neyman S, Braunewell K-H, O'Connell KE, Dev KK, Manahan-Vaughan D, Inhibition of the Interaction Between Group I Metabotropic Glutamate Receptors and PDZ-Domain Proteins Prevents Hippocampal Long-Term Depression, but Not Long-Term Potentiation, Frontiers in Synaptic Neuroscience, 11, 2019, p13Journal Article, 2019, DOI , TARA - Full Text
• Béchet S, O'Sullivan SA, Yssel J, Fagan SG, Dev KK., Fingolimod Rescues Demyelination in a Mouse Model of Krabbe's Disease., Journal of Neuroscience, 40, 2020, p3104 - 3118Journal Article, 2020, DOI
• Velasco-Estevez M, Gadalla KKE, Liñan-Barba N, Cobb S, Dev KK, Sheridan GK., Inhibition of Piezo1 attenuates demyelination in the central nervous system., Glia, 68, 2020, p356 - 375Journal Article, 2020, DOI
• Velasco-Estevez M, Rolle SO, Mampay M, Dev KK, Sheridan GK., Piezo1 regulates calcium oscillations and cytokine release from astrocytes., Glia, 68, 2020, p145 - 160Journal Article, 2020, DOI
• Chatterjee S, Dev KK, Kuhn RR, Sivasankaran R, 'GENES REGULATING INTRACELLULAR CHOLESTEROL TRAFFICKING AS TARGETS FOR TREATMENT OF CHOLESTEROL-RELATED DISEASES', Novartis AG Corporate Intellectual Property, WO/2007/141346, 2007Patent, 2007
• Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Pharma AG Patent Department, WO/2008/142073, 2008Patent, 2008
• Mattes H, Joachim N, David O, Dev KK. , 'BICYCLIC S1P RECEPTOR MODULATORS.', Novartis Institutes for Biomedical Research Inc, US2010/0179153, 2010Patent, 2010
• Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES. ', Novartis Pharma AG Patent Department, WO/2008/129029, 2008Patent, 2008
• David O, Mattes H, Joachim N, Dev KK., 'BENZAMIDAS UTILIZÁVEIS COMI MODULADORES DO RECEPTOR DE S1P. ', Dannemann, Siemsen, Bigler & Ipanema Moreira., BR/PI0811932, 2014Patent, 2014
• David O, Mattes H, Joachim N, Dev KK., 'DERIVADOS DE FTALAZINA E ISOQUINOLINA COM ATIVIDADES MODULADORAS DO RECEPTOR DE S1P.', Dannemann, Siemsen, Bigler & Ipanema Moreira., BR/PI0810123, 2014Patent, 2014
• Chatterjee S, Dev KK, Kuhn RR, Sivasankaran R. , 'GENES REGULATING INTRACELLULAR CHOLESTEROL TRAFFICKING AS TARGETS FOR TREATMENT OF CHOLESTEROL-RELATED DISEASES.', Novartis Pharma AG Patent Department. , EP2032599, 2009Patent, 2009
• Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Pharma AG Patent Department, EP2162427, 2010Patent, 2010
• Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Institutes for Biomedical Research Inc, US/2010/0197753, 2010Patent, 2010
• David O, Joachim N, Mattes H, Dev KK, 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Huang Gesheng Lin Bainan, CN/101687774, 2010Patent, 2010
• Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis AG Corporate Intellectual Property, CA/2686953, 2008Patent, 2008
• Dev KK, Mattes H, Joachim N, David O., 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Davies Collison Cave Pty Ltd, AU/2008/252943, 2009Patent, 2009
• Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis AG Corporate Intellectual Property, IN7219/DELNP/2009, 2012Patent, 2012
• Joachim N, Mattes H, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', CESAR RAMOS DE MIGUEL, MXMX/A/2009/011421, 2010Patent, 2010
• Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Novartis AG Corporate Intellectual Property, EP/2148863, 2010Patent, 2010
• Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Huang Gesheng Lin Bainan, CN/101679274, 2010Patent, 2010
• Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH S1P RECEPTOR MODULATING ACTIVITIES', Novartis AG Corporate Intellectual Property, CA/2684965, 2008Patent, 2008
• Dev KK, Mattes H, Joachim N, David O. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Davies Collison Cave Pty Ltd, AU/2008/240679, 2009Patent, 2009
• Mattes H, Joachim N, David O, Dev KK. , 'HTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING AVTIVITIES', Novartis AG Corporate Intellectual Property, IN/6695/DELNP/2009, 2010Patent, 2010
• Mampay M, Velasco-Estevez M, Rolle SO, Chaney AM, Boutin H, Dev KK, Moeendarbary E, Sheridan GK. , Spatiotemporal immunolocalisation of REST in the brain of healthy ageing and Alzheimer's disease rats., FEBS Open Bio, 11, 2021, p146 - 163Journal Article, 2021
• Velasco-Estevez M, Koch N, Klejbor I, Laurent S, Dev KK, Szutowicz A, Sailer AW, Rutkowska A. , EBI2 Is Temporarily Upregulated in MO3.13 Oligodendrocytes during Maturation and Regulates Remyelination in the Organotypic Cerebellar Slice Model. , Int J Mol Sci. , 22, 2021, p4342-Journal Article, 2021
• Clementino A, Velasco-Estevez M, Buttini F, Sonvico F, Dev KK. , Hybrid Nanoparticles as a Novel Tool for Regulating Psychosine-Induced Neuroinflammation and Demyelination In Vitro and Ex vivo., Neurotherapeutics, Online ahead print, 2021Journal Article, 2021
• Fagan SG, Bechet S, Dev KK. , Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer's Disease , Mol Neurobiol, Online ahead print, 2022Journal Article, 2022
• Mekhaeil M, Dev KK, Conroy MJ. , Existing evidence for the repurposing of PARP-1 inhibitors in rare demyelinating diseases , Cancers, Online ahead print, 2022Journal Article, 2022
• Velasco-Estevez, M. and Koch, N. and Klejbor, I. and Laurent, S. and Dev, K.K. and Szutowicz, A. and Sailer, A.W. and Rutkowska, A., Ebi2 is temporarily upregulated in mo3.13 oligodendrocytes during maturation and regulates remyelination in the organotypic cerebellar slice model, International Journal of Molecular Sciences, 22, (9), 2021Journal Article, 2021, DOI , URL
• S. Chatterjee, J.D. Szustakowski, N.R. Nanguneri, C. Mickanin, M.A. Labow, A. Nohturfft, K.K. Dev* and R. Sivasankaran. , Identification of Novel Genes and Pathways Regulating SREBP Transcriptional Activity. , PLoS ONE , 4, 2009, p5197-Journal Article, 2009, TARA - Full Text
• K.K. Dev, F. Mullershausen, H. Mattes, R. Kuhn, G. Bilbe, D. Hoyer, A. Mir, Brain S1P receptors: implication for fingolimod in the treatment of multiple sclerosis., Pharmacology & Therapeutics , 117, 2008, p77 - 93Journal Article, 2008
• Y. Senechal, P.H. Kelly, J.F. Cryan, F. Natt, and K.K Dev., Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. , J. Neurochemistry , 102, 2007, p1928 - 1940Journal Article, 2007, TARA - Full Text
• F. Mullershausen, L.M. Craveiro, Y. Shin, M. Cortes-Cros, F. Bassilana, M. Osinde, W.L. Wishart, D. Guerini, M. Thallmair, M.E. Schwab, R. Sivasankaran, K. Seuwen and K.K. Dev. , Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors., J. Neurochemistry , 102, 2007, p1151 - 1161Journal Article, 2007
• M. Osinde, F. Mullershausen and K.K. Dev. , Phosphorylated FTY720 stimulates ERK phosphorylation in Astrocytes via S1P receptors. Neuropharmacology, 52, 2007, p1210 - 1218Journal Article, 2007
• K.K. Dev, PDZ domain protein-protein interactions: a case study with PICK1, Current Topics in Medicinal Chemistry , 7, 2007, p3 - 20Journal Article, 2007
• J.F. Cryan and K.K. Dev, The Glutamatergic System as a Potential Therapeutic Target for the Treatment of Anxiety Disorders, PUBLISHED BOOK Handbook of Anxiety and Fear, Elsevier, Academic Press , 17, 2007, p269 - 301Journal Article, 2007
• K.K. Dev, S. Chatterjee, M. Osinde, D. Stauffer, H. Morgan, M. Kobialko, U. Dengler, H. Rueeger, B. Martoglio and G. Rovelli, Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals, Eur. J. Pharmacology , 540, 2006, p10 - 17Journal Article, 2006
• Y. Senechal, Y. Larmet and K.K. Dev, Unraveling in vivo functions of Amyloid Precursor Protein: insights from knockout and knockdown studies, Neurodegenerative Diseases , 3, 2006, p134 - 147Journal Article, 2006
• D. Hoyer and K. K. Dev, RNA interference as a therapeutic strategy for treating CNS disorders, Drug Discovery Today Therapeutic Strategies, 3, 2006, p451 - 456Journal Article, 2006
• K.K. Dev and J.M. Henley, The Schizophrenic Faces of PICK1, Trends Pharmacol Sci , 27, 2006, p574 - 579Journal Article, 2006, DOI , TARA - Full Text
• K.K. Dev, Using RNAi in the Clinic, Investigational Drugs Journal , 9, 2006, p279 - 282Journal Article, 2006
• C. Mahé, E. Loetscher, K.K. Dev, I. Bobirnac, U. Otten and P. Schoeffter., Serotonin 5-HT7 receptors coupled to induction of interleukin-6 in human microglial MC-3 cells, Neuropharmacology, 49, 2005, p40 - 47Journal Article, 2005
• K.L. Madsen, T. Beuming, M.Y. Niv, C-W. Chang, K.K. Dev, H. Weinstein and U. Gether, Delineating the complex PDZ domain binding specificity of PICK1, J. Biol Chem , 280, 2005, p20539 - 20548Journal Article, 2005
• K.K. Dev, Making protein interactions druggable: targeting PDZ domains, Nature Reviews Drug Discovery , 3, 2004, p1047 - 1056Journal Article, 2004
• E. Friedmann, M.K. Lemberg, A. Weihofen, K.K. Dev, U. Dengler, G. Rovelli and B. Martoglio, Consensus analysis of Signal Peptide Peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared to Presenilins, J. Biol Chem , 279, 2004, p50790 - 50798Journal Article, 2004, TARA - Full Text
• C. Mahé, M. Bernhard, I. Bobirnac, C. Keser, E. Loetscher, D. Feuerbach, K.K. Dev and P. Schoeffter, Functional expression of serotonin 5-HT7 receptor in human glioblastoma cell lines, Br. J. Pharmacolology, 143, 2004, p404 - 410Journal Article, 2004, TARA - Full Text
• K.K. Dev, S. Nakanishi and J.M. Henley, The PDZ domain of PICK1 differentially accepts Protein Kinase C-á and GluR2 as interacting ligands, J. Biol Chem , 279, 2004, p41393 - 41397Journal Article, 2004, TARA - Full Text
• A. Terashima, L. Cotton, K.K. Dev, G. Meyer, S. Zaman, F. Duprat, J.M. Henley, G.L. Collingridge and J.T.R. Isaac, Regulation of synaptic strength & AMPA receptor subunit composition by PICK1, J. Neuroscience , 24, 2004, p5381 - 5390Journal Article, 2004, TARA - Full Text
• K.K. Dev, K. Hofele, S. Barbieri, V. Buchman and H. van der Putten. , Part II: á-Synuclein and its molecular pathophysiological role in neurodegenerative disease, Neuropharmacology, 45, 2003, p14 - 44Journal Article, 2003
• K.K. Dev, H. van der Putten, B. Sommer and G. Rovelli, Part I: Parkin-associated proteins and Parkinson's Disease, Neuropharmacology, 45, 2003, p1 - 13Journal Article, 2003
• N. Finney, F. Walther, P-Y. Mantel, D. Stauffer, G. Rovelli and K.K. Dev., The cellular protein level of Parkin is regulated by its ubiquitin-like domain, J. Biol Chem, 278, 2003, p16054 - 16058Journal Article, 2003, TARA - Full Text
• K. Cho, J. Francis, H. Hirbec, K. Dev, M. Brown, J. Henley, and Z. I. Bashir, Regulation of kainate receptors by protein kinase C and metabotropic glutamate receptors, J. Physiology , 548, 2003, p723 - 730Journal Article, 2003
• H. Hirbec, J.C. Francis, S.E. Lauri, S.P. Braithwaite, F. Coussen, C. Mulle, K.K. Dev, V. Couthino, G. Meyer, J.T.R. Isaac, G.L. Collingridge and J.M. Henley, Rapid and differential regulation of AMPA and kainite receptors at hippocampal mossy fibre synapses by PICK1 and GRIP, Neuron , 37, 2003, p625 - 638Journal Article, 2003, TARA - Full Text
• H. Hirbec, O. Perestenko, A. Nishimune, G. Meyer, S. Nakanishi, J.M. Henley, and K.K. Dev, The PDZ Proteins PICK1, GRIP and Syntenin bind multiple glutamate receptor subtypes, J. Biol Chem , 277, 2002, p15221 - 15224Journal Article, 2002, TARA - Full Text
• E. Vernon, G. Meyer, L. Pickard, K. Dev, E. Molnar, G.L. Collingridge and J.M. Henley, GABAB receptors couple directly to the transcription factor ATF4, Molecular Cell Neuroscience , 17, 2001, p637 - 645Journal Article, 2001
• K.K. Dev, S. Nakanishi and J. M. Henley, Regulation of mGlu7 receptors by proteins that interact with the intracellular C-terminus, Trends Pharmacol Sci , 22, 2001, p355 - 361Journal Article, 2001
• M.I. Daw, R. Chittajallu, Z.A. Bortolotto, K.K. Dev, F. Duprat, J.M. Henley, G.L. Collingridge and J.T.R. Isaac, PDZ Proteins interacting with c-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses, Neuron , 28, 2000, p873 - 886Journal Article, 2000, TARA - Full Text
• K.K. Dev, Y. Nakajima, J. Kitano, S. P. Braithwaite, J. M. Henley and S. Nakanishi, PICK1 interacts with and regulates PKC phosphorylation of mGluR7, J. Neuroscience , 20, 2000, p7252 - 7257Journal Article, 2000
• K.K. Dev, A. Nishimune, J.M. Henley and S. Nakanishi, The protein kinase Cá binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits, Neuropharmacology, 38, 1999, p635 - 644Journal Article, 1999
• M.J. Keir, M.J. Barakat, K.K. Dev, H. Bittiger, B. Bettler and J.M. Henley, Characterisation of GABAB receptor from rat cerebellum using novel antagonist [3H]CGP 62349, Molecular Brain Research , 71, 1999, p279 - 289Journal Article, 1999
• K.K. Dev and J.M. Henley, The Regulation of AMPA receptor binding sites, Molecular Neurobiology , 17, 1998, p33 - 58Journal Article, 1998
• K.K. Dev, T. Honoré and J.M. Henley, Different effects of Phospholipase A2 on agonist binding to hippocampal, cortical and recombinant homomeric AMPA receptors, Neuroscience Letters , 246, 1998, p25 - 28Journal Article, 1998
• K.K. Dev, C. Foged, H. Andersen, T. Honoré and J.M. Henley, High affinity binding sites for [125I]-labelled pancreatic secretory phospholipase A2 in rat brain, Molecular Brain Research , 49, 1997, p120 - 126Journal Article, 1997
• K.K. Dev, V. Petersen, T. Honoré and J.M. Henley, Pharmacology and regional distribution of [3H] 6-nitro-7-sulphamoylbenzo(F)quinoxaline-2-3 dione ([3H]NBQX) binding to rat brain, J. Neurochemistry , 67, 1996, p2609 - 2612Journal Article, 1996
• K.K. Dev, P.J. Roberts, and J.M. Henley, Characterisation of the interaction between guanyl nucleotides and AMPA receptors in rat brain, Neuropharmacology, 35, 1996, p1583 - 1593Journal Article, 1996
• R. Chittajallu, M. Vignes, K.K. Dev, J.M. Barnes, G.L. Collingridge and J.M. Henley, Regulation of glutamate release by presynaptic kainate receptors in the hippocampus, Nature, 379, 1996, p78 - 81Journal Article, 1996
• K.K. Dev, T. Honoré and J.M. Henley, Phospholipase A2 down-regulates the affinity of [3H]AMPA binding to rat cortical membranes, J. Neurochemistry , 65, 1995, p184 - 191Journal Article, 1995
• Barnes JM, Dev KK and Henley JM, Cyclothiazide unmasks AMPA-evoked stimulation of [3H]-L-glutamate release from rat hippocampal synaptosomes, Br. J. Pharmacology , 113, 1994, p339 - 341Journal Article, 1994, TARA - Full Text
• Dev KK and Morris BJ, Modulation of a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) binding sites by nitric oxide, Journal of Neurochemistry , 63, 1994, p946 - 952Journal Article, 1994
• P. Dutta, D. Deb, L. Dargahi, D. Ivankovic, K.K. Dev, The GPR37/PAEL Receptor - Finding a Way to the Cell Surface., Drug Discovery , 7, 2010, p36 - 39Journal Article, 2010
• H. Mattes, K.K. Dev, R. Bouhelal, C. Barske, F. Gasparini, D. Guerini, A.K. Mir, D. Orain, M. Osinde, A. Picard, C. Dubois, E. Tasdelen, S. Haessig. , Design and synthesis of selective and potent orally active S1P5 agonists., Chem Med Chem , 5, 2010, p1693 - 1696Journal Article, 2010, TARA - Full Text
• Claus Rieker, Kumlesh K. Dev, Katja Lehnhoff, Samuel Barbieri, Iwona Ksiazek, Sabine Kauffmann, Simone Danner, Heinrich Schell, Cindy Boden, Markus A. Ruegg, Philipp J. Kahle, Herman van der Putten, Derya R. Shimshek, Neuropathology in Mice Expressing Mouse Alpha-Synuclein, PLoS ONE, 6, (9, e24834), 2011Journal Article, 2011, DOI , URL , TARA - Full Text
• Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS Complex: New Drugs for Depression?, Pharmacology & Therapeutics, 133, 2012, p218 - 229Journal Article, 2012, TARA - Full Text
• Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS complex: New drugs for depression?, Pharmacology and Therapeutics, 133, (2), 2012, p218-29Journal Article, 2012, DOI , URL
• O'Connell K, Thakore J, Dev KK, Levels of S100B are raised in female patients with schizophrenia., BMC psychiatry, 13, 2013, p146Journal Article, 2013, DOI , TARA - Full Text
• Healy LM, Sheridan GK, Pritchard AJ, Rutkowska A, Mullershausen F, Dev KK, Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes., British journal of pharmacology, 169, (5), 2013, p1114-1129Journal Article, 2013, DOI , TARA - Full Text
• Doucet MV, Levine H, Dev KK, Harkin A, Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice., Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38, (8), 2013, p1575-1584Journal Article, 2013, DOI , TARA - Full Text
• Bolia A, Gerek ZN, Keskin O, Banu Ozkan S, Dev KK, The binding affinities of proteins interacting with the PDZ domain of PICK1., Proteins, 80, (5), 2012, p1393-408Journal Article, 2012
• Sheridan GK, Dev KK, S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures., Glia, 60, (3), 2012, p382-92Journal Article, 2012
• Senechal Y, Prut L, Kelly PH, Staufenbiel M, Natt F, Hoyer D, Wiessner C, Dev KK, Increased exploratory activity of APP23 mice in a novel environment is reversed by siRNA., Brain research, 1243, 2008, p124-33Journal Article, 2008
• Osinde M, Clavaguera F, May-Nass R, Tolnay M, Dev KK, Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation., Neuropathology and applied neurobiology, 34, (5), 2008, p523-31Journal Article, 2008
• Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A, Reed SI, SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis., Genes & development, 22, (2), 2008, p252-64Journal Article, 2008, DOI , TARA - Full Text
• Senechal Y, Kelly PH, Dev KK, Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning., Behavioural brain research, 186, (1), 2008, p126-32Journal Article, 2008
• Pritchard, AJ, Mir, AK, Dev, KK, Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures, PLOS ONE, 9, (6), 2014, p0099444-Journal Article, 2014, DOI , TARA - Full Text
• Sheridan, GK, Dev, KK, Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations, SCIENTIFIC REPORTS, 4, 2014, p5051-Journal Article, 2014, DOI , TARA - Full Text
• Dutta, P., O'Connell, K.E., Ozkan, S.B., Sailer, A.W., Dev, K.K., The protein interacting with C-kinase (PICK1) interacts with and attenuates parkin-associated endothelial-like (PAEL) receptor-mediated cell deat, Journal of Neurochemistry, 130, (3), 2014, p360-373Journal Article, 2014, DOI , TARA - Full Text
• O'Connell, K.E., Frei, P. , Dev, K.K., The premium of a big pharma license deal, Nature Biotechnology, 32, (7), 2014, p617-619Journal Article, 2014, DOI
• Shrestha, R., Millington, O., Brewer, J., Dev, K.K., Bushell, T.J., Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways, Neuropharmacology, 76, (a), 2014, p184-193Journal Article, 2014, DOI
• O'Connell, KE, Thakore, J, Dev, KK, Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine, SCHIZOPHRENIA RESEARCH, 156, (1), 2014, p1-8Journal Article, 2014, DOI
• Frei, P., Dev, K.K., Drug dealers: $20 trillion of in-licensing payments (Editorial), Drug Discovery Today, 18, (21-22), 2014, p1027-1029Journal Article, 2014, DOI
• Pritchard, A.J., Dev, K.K. , The role of sphingosine 1-phosphate receptors in the treatment of demyelinating diseases (Review), Future Neurology, 8, (5), 2013, p569-581Journal Article, 2013, DOI
• O'Sullivan, C., Dev, K.K. , The structure and function of the S1P1 receptor (Review), Trends in Pharmacological Sciences, 34, (7), 2013, p401-412Journal Article, 2013, DOI

• Dev KK, 6th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 186, 2017, p281 - 298Journal Article
• Dev KK, 5th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 185, 2016, p169 - 185Journal Article
• Dev KK, 4th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 184, 2015, p1 - 18Journal Article
• Dev KK, 3rd Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci. , 183, 2014, p71 - 85Journal Article
• Dev KK, 2nd Annual Meeting. Block MS Ireland. Neuroprotection: At the cellular, in vivo and clinical level., Irish J Med. Sci., 182, 2013, p1 - 13Journal Article
• Dev KK, Neurology, Professor Kumlesh Dev sets out Ireland's position on brain disease. Irish Independent (Supplement), 2015, -Miscellaneous

My research is focused in areas of Drug Development and Neuroscience. My research integrates fields of molecular biology, cell science, and drug discovery. It integrates the areas of cell biology, medicine and pharmaceuticals. I established the Drug Development group at Trinity, which investigates mechanisms underlying brain diseases, particularly demyelinating diseases such as Multiple Sclerosis, and also with a focus on rare paediatric illnesses including Krabbes disease (KD). KD causes fatality in infants and has no cure. My group has identified new compounds, repositioned marketed drugs, developed novel nanoparticle technology and created nasal delivery methods that demonstrate efficacy models of KD. These findings are published in top-tier neuroscience and neurotherapeutic journals and are of international recognition. This research is translational, where the developed technologies are on a potential path of clinical development, subject of patent application, commercialisation and the basis of EU grant applications, supported by Enterprise Ireland. My research has transformed our understanding of how marketed drugs used in Multiple Sclerosis work, and how they directly regulate brain cells. This work is pioneering, highly cited and uncovered novel cell mechanisms leading to development of new therapeutic strategies. This work demonstrates an ongoing transformational nature of my activities. My research is competitively recognised and well supported by national and international funding agencies as well as multinational pharmaceutical industry and biotech. I have been awarded over €5.7 million in funding, published almost 100 papers and have an H-index of over 40. I am a board member and reviewer of several international journals, advisor and consultant to large pharmaceutical and biotech companies and I have been President of Frontier of Neurology Ireland for 7 years, bringing to Ireland and Trinity links from across Europe and US, and bringing support from multiple large pharma and research funding agencies. My work has also been highlighted in national press in the area of neurology and drug development. I have significant expertise in drug development and a global network within multiple pharma and biotech industry. I have provided leadership to large research and drug discovery projects and successfully delivered follow-on compounds of marketed drugs, for Multiple Sclerosis. I have published extensively in my area of research of brain cell biology, specifically glial cells. The journal Glia is the highest journal in this field in which my research is being published on a yearly basis. A pubmed search in my focussed area indicates 10% of articles being from my group, many are highly cited. The approaches used by my group, integrating human brain cells and brain slice studies are also unique. The drug testing platform established in my group attracts multiple industry collaborations. I am regularly invited as a Consultant to guide and review drug development projects. I have provided Consultant assistance to drug development of nearly 100 various pharma and biotech companies. With these activities, I have a world leader recognition in my area of drug development. My mission is to teach within the emerging field of drug development as well as develop new medicines.

Biochemistry, Molecular & Cellular Biology, Immunity and Infection (including Rheumatology & Inflammatory disease), Medical Engineering, Biotechnology and devices (including medical laboratory technologies and informatics), Regenerative and Developmental Biology, Nano-technology, Mental Health (including Psychiatry and Clinical Psychology), Neuroscience and clinical neurology, Pharmacology & Toxicology including drug formulation and delivery,

• Wellcome Trust, Over €0.65 million, Multiple Awards latest award 2021
• Editor, Special Issue, Cancers 2021
• Consortium Trinity Lead, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School latest award 2022
• Irish Research Council, Over €0.14 million Multiple Awards latest award 208
• Charities, Over €0.60 million, Multiple Awards latest award 2007
• Science Foundation Ireland, Over €0.28 million, Multiple Awards latest award 2017
• Health Research Board, Over €1.09 million, Multiple Awards latest award 2018
• Editor, Special Issue, Frontiers in Behavioral Neuroscience 2022
• Industry Over €0.96 million, Multiple Awards latest award 2018
• Project Collaborator, HEA, PRTLI, Ireland Award latest award 2014
• Work Package Lead and Course Director, HEA, Human Capital Initiative (Pillar 3) latest award 2021
• Work Package Lead and Course Director, HEA, Human Capital Initiative (Pillar 1) latest award 2020
• External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland (Recognises leadership in research and teaching in Neuroscience) 2020-Current
• Editor, Special Issue, Neuropharmacology 2017
• Editor, Special Issue, Current Drug Targets 2016
• Enterprise Ireland, Over €0.14 million, Multiple Awards latest award 2021
• Fellow, Trinity College Dublin (FTCD) 2014-Current
• Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy 2020-Current

• Editorial Board Member, Brain, Behavior, and Immunity Current
• Editorial Board Member, Journal of Biological Chemistry 2011
• President, Frontiers in Neurology Ireland (FIN) 2017
• Council Member, Swiss Tissue Culture Society 2006
• Council Member, Society for Neuroscience Ireland 2015
• Editorial Board Member, Scientific Reports 2019
• Member, Society for Neuroscience Current
• Consortium Member, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School Current
• Fellow, Trinity College Dublin (FTCD) Current

• Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy 2020-Current
• Editor, Special Issue In Current Drug Targets (Common Receptor Signalling in Glial and Immune Cells), (Impact Factor 3.030) 2016
• Editorial Board Member, Scientific Reports (Impact Factor 4.379, Quartile Q1) 2014-2019
• Editor, Frontiers in Behavioral Neuroscience (Drug Development in Rare Demyelinating Diseases), (4th cited open access in Neurosci) 2022
• Editorial Board Member, Brain, Behavior, and Immunity (Impact Factor 7.217, Quartile Q1, 16/156 Psychiatry Journals) 2016-Current
• President, Frontiers in Neurology Ireland (FIN) (Held for 7 years, in recognition within area of Drug Development & Neurology) 2011-2017
• Consortium Member, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School, (EU-collaborative network providing training opportunities to PhD students in Trinity) 2020-Current
• Editorial Board Member, Journal of Biological Chemistry (Impact Factor 5.157, Quartile Q1, In top 75% Biochem & Cell Journals) 2005-2011
• Member, Society for Neuroscience (Recognised as the major neuroscience society globally) 2000-Current
• Editor, Special Issue In Neuropharmacology (Lipid Sensing G Protein-Coupled Receptors in the CNS), (Impact Factor 5.251) 2017
• Council Member, Swiss Tissue Culture Society (Held for 2 years, international society focused on cell-based drug discovery) 2005-2006
• External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland 2020-Current
• External Examiner, PhD Thesis (External Examiner of multiple PhD Thesis, approx. 1-2 per year) 2009-Current
• External Consultant, Pharma and Biotech Industries (Consultant Role in scientific review of multiple biotech and pharma companies) 2009-Current
• Editor, Special Issue In Cancers (Cangliomics - Repositioning Drugs for Cancer Gliomas), (Impact Factor 6.639) 2021-Current
• Council Member, Society for Neuroscience Ireland (Held for 3 years, developing travel grant applications in the society) 2013-2015